Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul>
<li>Grace is a clinical-stage, biotechnology company focused on rare disease.</li>
<li>Its lead program is for GTX-104, a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).</li>
<li>Other programs include GTX-102 for Ataxia Telangiectasia &amp; GTX-101 for postherpetic neuralgia.</li>
</ul>


Grace is a clinical-stage, biotechnology company focused on rare disease.
Its lead program is for GTX-104, a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).
Other programs include GTX-102 for Ataxia Telangiectasia &amp; GTX-101 for postherpetic neuralgia.


Grace Therapeutics, Inc:  Initiating Coverage – From Confusion to Infusion

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

<ul><li>Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhages</li><li>Lead asset GTX-104 is the primary focus of their development efforts</li><li>Successful PIPE offering and enrollment in Phase 3 trial put Acasti Pharma on track for potential FDA approval</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhagesLead asset GTX-104 is the primary focus of their development effortsSuccessful PIPE offering and enrollment in Phase 3 trial put Acasti Pharma on track for potential FDA approvalThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Acasti Pharma Inc (ACST) - Wednesday, Jul 10, 2024

United States

Grace Therapeutics, Inc. operates as a late-stage biopharma company. The Company focuses on drug delivery and technologies addressing rare and orphan diseases. Grace Therapeutics serves clients in Canada and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grace Therapeutics (GRCE US)

Grace Therapeutics, Inc: Initiating Coverage – From Confusion to Infusion

Grace is a clinical-stage, biotechnology company focused on rare disease.Its lead program is for GTX-104, a novel injectable formulation of...

Zacks Small Cap Research

Acasti Pharma Inc (ACST) - Wednesday, Jul 10, 2024

Acasti Pharma is making progress in developing IV nimodipine for acute subarachnoid hemorrhages. Lead asset GTX-104 is the primary focus of their...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)